Vol. 2 No. 11 (2022)
Reimbursement Recommendations

Pembrolizumab (Keytruda)

Published November 22, 2022

Key Messages

  • CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of stage IIB/IIC melanoma following complete resection only if certain conditions are met.
  • Keytruda should only be covered to treat patients who have stage IIB or stage IIC melanoma who have not received prior treatment beyond surgery.
  • Keytruda should only be reimbursed if prescribed in an outpatient oncology clinic and supervised by a specialist who has experience in delivery of immunotherapy, and if the cost of Keytruda is reduced.